title: Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.
abstract: This report describes outpatient (OP) administration of clofarabine in older patients (≥60 years) with untreated acute myelogenous leukemia (AML). Overall, 112 patients underwent clofarabine induction. Clofarabine was administered to 35 OPs for a total of 72 OP cycles, with 81% of these cycles representing consolidation treatment. Median length of hospital stay was 0-6 days and 5-25 days across OP and inpatient (IP) cycles, respectively. The most common adverse events (AEs) were nausea, vomiting, diarrhea, febrile neutropenia, edema, hypokalemia and pneumonia. The overall frequency of treatment-emergent grade ≥3 AEs and serious AEs was generally not different with IP or OP administration of clofarabine. No deaths were reported within 30 days following OP or IP consolidation cycles. In the appropriately selected older patient, OP administration of clofarabine consolidation appears feasible, is as well tolerated as IP administration and has potential to contribute to the quality of life in elderly patients with AML.
authors: Division of Hematology/Oncology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA. dclaxton@hmc.psu.edu
authors: David
authors: D
authors: Claxton
authors: Harry P
authors: HP
authors: Erba
authors: Stefan
authors: S
authors: Faderl
authors: Martha
authors: M
authors: Arellano
authors: Roger M
authors: RM
authors: Lyons
authors: Tibor
authors: T
authors: Kovacsovics
authors: Janice
authors: J
authors: Gabrilove
authors: Dirk
authors: D
authors: Huebner
authors: Pritesh J
authors: PJ
authors: Gandhi
authors: Hagop
authors: H
authors: Kantarjian
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced; D000227:Adenine Nucleotides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000553:Ambulatory Care; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077866:Clofarabine; D060830:Consolidation Chemotherapy; D004334:Drug Administration Schedule; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced; D007297:Inpatients / Q000706:statistics & numerical data; D007902:Length of Stay; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D010045:Outpatients / Q000706:statistics & numerical data; D011014:Pneumonia / Q000209:etiology; D011788:Quality of Life
chemical_list: D000227:Adenine Nucleotides; D000964:Antimetabolites, Antineoplastic; D001087:Arabinonucleosides; D000077866:Clofarabine